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Abstract: Cardiovascular morbidity and mortality are several-fold higher in patients with advanced
chronic kidney disease (CKD) and end-stage renal disease (ESRD) than in the general population.
Hyperhomocysteinemia has undoubtedly a central role in such a prominent cardiovascular burden.
The levels of homocysteine are regulated by methyl donors (folate, methionine, choline, betaine),
and cofactors (vitamin B6, vitamin B12,). Uremia-induced hyperhomocysteinemia has as its main
targets DNA methyltransferases, and this leads to an altered epigenetic control of genes regulated
through methylation. In renal patients, the epigenetic landscape is strictly correlated with the
uremic phenotype and dependent on dietary intake of micronutrients, inflammation, gut microbiome,
inflammatory status, oxidative stress, and lifestyle habits. All these factors are key contributors
in methylome maintenance and in the modulation of gene transcription through DNA hypo- or
hypermethylation in CKD. This is an overview of the epigenetic changes related to DNA methylation
in patients with advanced CKD and ESRD. We explored the currently available data on the molecular
dysregulations resulting from altered gene expression in uremia. Special attention was paid to
the efficacy of B-vitamins supplementation and dietary intake of methyl donors on homocysteine
lowering and cardiovascular protection.
Keywords: chronic kidney disease; cobalamin; DNA methylation; epigenetic; folic acid; methyl
donors; vitamin B6; vitamin B12 sublingual formulation
1. Introduction
It is well known that chronic kidney disease (CKD) confers a markedly increased cardiovascular
risk, especially when it progresses to end- stage renal disease (ESRD) [1,2]. Among the non-
traditional and uremia-related risk factors accounting for such prominent cardiovascular burden,
hyperhomocysteinemia (HHcy) is commonly found in CKD patients because of impaired renal
metabolism and excretion [3]. In the general population, as well as in patients with kidney disease,
elevated homocysteine levels promote atherosclerosis through increased oxidative stress, impaired
endothelial function, and induction of thrombosis (Figure 1).
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Homocysteine is regulated by the vitamin B group, namely vitamins B6 (pyridoxine), B9 (folic 
acid), and B12 (cobalamin). However, despite the beneficial effects of supplementation with these 
vitamins found on HHcy in the general population, less encouraging and sometimes inconsistent 
data have been reported in ESRD patients [4–8]. 
In many cases, the literature has shown that dialysis patients are a peculiar population whose 
response to certain factors is opposite of that of the general population, a condition that has been 
referred to as “reverse epidemiology” [9]. An example is represented by hypocholesterolemia, 
identified as a predictor of increased mortality in dialysis patients [10,11]. Similarly, we have 
previously demonstrated that higher BMI protects ESRD patients against coronary artery 
calcifications [12]. In line with this evidence, very low homocysteine levels seem to be associated with 
worse clinical outcomes, longer hospitalization, and higher all-cause and cardiovascular deaths in 
ESRD patients [9,13,14]. The combined effect of protein-energy malnutrition and wasting 
inflammation might partly explain this apparent paradox of the inverse relationship between 
homocysteine levels and mortality in ESRD patients [14]. However, it remains an open question 
whether HHcy is a consequence rather than a causal factor of cardiovascular complications in uremic 
patients, or even just the tip of the iceberg of a complex underlying pathway involving other key 
molecules [3]. 
Different experimental and clinical studies highlighted how elevated circulating levels of 
homocysteine result in intracellular increase in S-adenosylhomocysteine, a competitive inhibitor of 
methyltransferase, which in turn has been identified as a risk factor of cardiovascular events. Uremia-
induced HHcy and the subsequent elevation of intracellular S-adenosylhomocysteine has as main 
targets DNA methyltransferases (DNMTs), and this leads to altered expression of genes regulated 
through methylation [15]. 
Epigenetic changes able to affect CKD and to influence the variability of uremic phenotypes are 
modulated by several factors, including diet and nutritional status, inflammation, cytokine 
polymorphisms, gut microbiome, and lifestyle habits [16,17]. In particular, HHcy, inflammatory 
status and oxidative stress are the key contributors in the modulation of gene transcription through 
DNA hypo- or hypermethylation in CKD [18–20]. 
This is an overview of the epigenetic changes related to DNA methylation in patients with 
advanced CKD and ESRD. In particular, we reviewed the current knowledge on the molecular 
dysregulations resulting from altered gene expression in uremia. A special focus was given to the 
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Homocysteine is regulated by the vitamin B group, namely vitamins B6 (pyridoxine), B9 (folic
acid), and B12 (cobalamin). However, despite the beneficial effects of supplementation with these
vitamins found on HHcy in the general population, less encouraging and sometimes inconsistent data
have been reported in ESRD patients [4–8].
In many cases, the literature has shown that dialysis patients are a peculiar population whose
response to certain factors is opposite of that of the general population, a condition that has been
referred to as “reverse epidemiology” [9]. An example is represented by hypocholesterolemia,
identified as a predictor of increased mortality in dialysis patients [10,11]. Similarly, we have previously
demonstrated that higher BMI protects ESRD patients against coronary artery calcifications [12]. In line
with this evidence, very low homocysteine levels seem to be associated with worse clinical outcomes,
longer hospitalization, and higher all-cause and cardiovascular deaths in ESRD patients [9,13,14].
The combined effect of protein-energy malnutrition and wasting inflammation might partly explain
this apparent paradox of the inverse relationship between homocysteine levels and mortality in ESRD
patients [14]. However, it remains an open question whether HHcy is a consequence rather than a
causal factor of cardiovascular complications in uremic patients, or even just the tip of the iceberg of a
complex underlying pathway involving other key molecules [3].
Different experimental and clinical studies highlighted how elevated circulating levels of
homocysteine result in intracellular increase in S-adenosylhomocysteine, a competitive inhibitor
of methyltransferase, which in turn has been identified as a risk factor of cardiovascular events.
Uremia-induced HHcy and the subsequent elevation of intracellular S-adenosylhomocysteine has as
main targets DNA methyltransferases (DNMTs), and this leads to altered expression of genes regulated
through methylation [15].
Epigenetic changes able to affect CKD and to influence the variability of uremic phenotypes
are modulated by several factors, including diet and nutritional status, inflammation, cytokine
polymorphisms, gut microbiome, and lifestyle habits [16,17]. In particular, HHcy, inflammatory status
and oxidative stress are the key contributors in the modulation of gene transcription through DNA
hypo- or hypermethylation in CKD [18–20].
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This is an overview of the epigenetic changes related to DNA methylation in patients with
advanced CKD and ESRD. In particular, we reviewed the current knowledge on the molecular
dysregulations resulting from altered gene expression in uremia. A special focus was given to the
efficacy of B-vitamins supplementation and dietary intake of methyl donors on homocysteine lowering
and cardiovascular protection.
2. Methyl-Donor Mediated Epigenetic Effects in CKD
For most genes, DNA hypomethylation commonly results in active transcription, whereas
hypermethylation leads to gene silencing since DNA is packaged in an inactive chromatin form.
DNA methylation is catalyzed by DNMTs, an enzyme family responsible for the transfer of a
methyl group from S-adenosyl methionine (SAM) to the carbon at position 5 of the cytosine residue
of the dinucleotide CpG. On the other hand, gene activation occurs through DNA demethylation
catalyzed by dioxygenases of the TET (ten-eleven translocation) protein family composed of TET1,
TET2, and TET3 enzymes (Figure 2).
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interpretation relates genomic hypomethylation to accelerated aging. However, it should also be 
considered that the interindividual variability of clinical conditions arises from a more complex 
network, involving promoters and regulatory regions that can be in turn modulated by hyper- or 
hypomethylation The existing mechanistic link between dietary and epigenetic factors regulates 
ageing and declining renal function throughout lifetime. In particular, recent evidence has 
highlighted how epigenetic dysregulation in CKD is dependent on nutrient-sensing pathways. Thus, 
dietary variations related to socioeconomic conditions or eating habits can differentially affect renal 
failure progression, related to genomic hypomethylation and inflammatory status. The main factors 
driving the so-called “inflammaging” may contribute to accelerated senescence and to the 
establishment of a proinflammatory environment [21,22]. 
For these reasons, the term “methylome” has been introduced to define the pattern of nucleic 
acid methylations in the genome or in a specific tissue [23]. 
The homeostasis of methylome relies on the availability of methyl donors, mainly folic acid, 
methionine, choline, and betaine. Nevertheless, the impact of their dietary intake on uremic state and 
ultimately on the epigenetic regulation in CKD is not fully elucidated. Impairments in DNA 
methylation landscape represent an important molecular feature in several pathologies, including 
renal diseases [17,24–27]. 
In mammalians, DNA methylation is the process by which methyl groups (CH3) are transferred 
from SAM to the 5-position of cytosine residues to form 5-methylcytosine. This biological pathway is 
regulated by DNMTs, a highly preserved class of enzymes, with several molecular functions not 
limited to gene activation and silencing through methylation, but also other post-transcriptional and 
post-translational modifications [28]. Mammalians’ genomes are generally methylated at CpG 
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The progression towards renal failure is related to a combination of factors, namely oxidative
stress, inflammation, and uremic toxins, that contribute to epigenetic dysregulation. In CKD, a shared
interpretation relates genomic hypomethylation to accelerated aging. However, it should also be
considered that the interindividual variability of clinical conditions arises from a more complex
network, involving promoters and regulatory regions that can be in turn modulated by hyper- or
hypomethylation The existing mechanistic link between dietary and epigenetic factors regulates
ageing and declining renal function throughout lifetime. In particular, recent evidence has highlighted
how epigenetic dysregulation in CKD is dependent on nutrient-sensing pathways. Thus, dietary
variations related to socioeconomic conditions or eating habits can differentially affect renal failure
progression, related to genomic hypomethylation and inflammatory status. The main factors driving
the so-called “inflammaging” may contribute to accelerated senescence and to the establishment of a
proinflammatory environment [21,22].
For these reasons, the term “methylome” has been introduced to define the pattern of nucleic acid
methylations in the genome or in a specific tissue [23].
The homeostasis of methylome relies on the availability of methyl donors, mainly folic acid,
methionine, choline, and betaine. Nevertheless, the impact of their dietary intake on uremic state
and ultimately on the epigenetic regulation in CKD is not fully elucidated. Impairments in DNA
methylation landscape represent an important molecular feature in several pathologies, including
renal diseases [17,24–27].
Nutrients 2020, 12, 1234 4 of 20
In mammalians, DNA methylation is the process by which methyl groups (CH3) are transferred
from SAM to the 5-position of cytosine residues to form 5-methylcytosine. This biological pathway
is regulated by DNMTs, a highly preserved class of enzymes, with several molecular functions not
limited to gene activation and silencing through methylation, but also other post-transcriptional
and post-translational modifications [28]. Mammalians’ genomes are generally methylated at CpG
dinucleotide sites, thus allowing the binding of proteins and chromatin remodeling factors able to
repress transcription. On the other hand, when DNA regions rich in CpG sites, known as “CpG
islands”, are hypomethylated, this allows an open chromatin structure, the binding of transcription
factors, and the creation of a transcriptionally “permissive” chromatin state [29].
In CKD, the machinery that controls methyl transfer reactions is significantly influenced by the
metabolic alterations found in uremic state, since uremic toxins themselves have been proven to be
related to methyl metabolism and sulfur amino acid metabolism [30,31].
A prime example of the link between uremia and epigenetic changes occurring in in CKD is MTHFR
gene, coding for the enzyme MTHFR, which catalyzes the reduction of 5,10-methylenetetrahydrofolate
(methylene THF) to 5-methyl-THF [32,33]. A study by Ghattas et al. on 96 ESRD patients and healthy
subjects matched for number, age, sex, and race, reported a higher degree of MTHFR promoter
methylation in uremic patients compared to the controls. Moreover, silenced MTHFR gene expression
resulted in significantly lower eGFR [34]. Whether this inverse correlation between homocysteine
levels and renal function is reversible by dietary and therapeutic interventions is still debated.
In patients who progress towards ESRD and need a renal replacement therapy, the literature
has not highlighted substantial differences in terms of methylation profiles with respect to earlier
CKD stages.
Hsu et al. investigated the impact of the uremic milieu on DNA methylation and DNA
methyltransferase (DNMT) expression, comparing 20 patients under chronic hemodialysis with
20 healthy controls with similar age, gender distribution, and BMI. As expected, dialysis patients
showed higher levels of several inflammatory and uremia-related parameters, namely blood urea
nitrogen (BUN), serum creatinine, uric acid, calcium, phosphorus, iPTH, cholesterol, CRP, indoxyl
sulphate, p-cresol sulphate, and homocysteine. Conversely, the expression of DNMT 1 and 3a did not
differ significantly between the groups. Moreover, global DNA methylation was not associated with
the levels of uremic toxins and homocysteine, indicating that DNA methylation status may not change
significantly in patients undergoing an intensive intervention like hemodialysis [35].
However, the different dialysis techniques seem to affect differently the global DNA methylation
status. Ghigolea et al. compared whole blood DNA methylation in 40 on-line hemodiafiltration
(HDF) patients vs. 40 high-flux hemodialysis patients vs. 10 control subjects. The results showed
a significantly higher methylation degree in hemodialysis patients compared to on-line HDF and
controls, suggesting that dialysis technique might affect the degree of inflammation through aberrant
DNA hypermethylation [36].
3. Effects of Supplementation and Dietary Intake of B-Vitamins and Methyl Donors on
Epigenetic Changes in Renal Disease
Nowadays, it is well-assessed that the epigenetic landscape in CKD is strictly correlated with the
uremic phenotype and dependent on dietary intake of micronutrients that give an essential contribution
to methylome maintenance and epigenetic regulation, as methyl donors (folate, methionine, choline,
betaine), or as cofactors (vitamin B12, vitamin B6) [37].
Table 1 summarizes the main dietary sources of folate, vitamin B12, methionine, choline, betaine,
and vitamin B6, with the related food content and RDA (Recommended Dietary Allowance).
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Table 1. Main dietary sources of folate, vitamin B12, methionine, choline, betaine, and vitamin B6,
related food content, and RDA (Recommended Dietary Allowance).
Foods Content RDA (%)
Folate
Asparagus 263 µg/100 g 66
Cooked spinaches 262 µg/100 g 66
Cooked lentils 179 µg/100 g 45
Black eyed peas 179 µg/100 g 45
Romaine lettuce 114 µg/100 g 29
Great grains cereals 114 µg/100 g 29
Cooked broccoli 78 µg/100 g 20
Sunflower seeds 76 µg/100 g 19
Fresh orange juice 75 µg/100 g 19
Cooked beets 69 µg/100 g 17
Kidney beans 65 µg/100 g 16
Vitamin B12
Clams 98.9 µg/100 g 4944
Liver 85.6 µg/100 g 4280
Fortified cereals 20.3 µg/100 g 1017
Mackerel 19 µg/100 g 949
Beef 7.5 µg/100 g 376
Crab 6.7 µg/100 g 335
Swiss cheese 3 µg/100 g 150
Fortified tofu 1.4 µg/100 g 69
Eggs (whole) 0.8 µg/100 g 41
Skimmed milk 0.5 µg/100 g 26
Vitamin B6
Cornflakes/branflakes 1.4 mg/100 g 107
Lean pork meat 0.72 mg/100 g 55.3
Lean rump meat 0.65 mg/100 g 49.8
Chicken/turkey
breast 0.63 mg/100 g 48.6
Lamb’s kidney 0.56 mg/100 g 43.1
Calf’s liver 0.48 mg/100 g 36.9
Lean minced beef 0.42 mg/100 g 32.3
Avocado 0.36 mg/100 g 27.7
Grilled sardines 0.36 mg/100 g 27.7
Mackerel/plaice 0.27 mg/100 g 20.9
Pomegranate 10.26 mg/100 g 20.1
Methionine
Brazil nuts 1124 mg/100 g 154
Poultry 931 mg/100 g 128
Red meat 905 mg/100 g 124
Tuna 885 mg/100 g 122
Pork meat 850 mg/100 g 117
Eggs (whole) 332 mg/100 g 45
Ricotta cheese 284 mg/100 g 39
Tofu 211 mg/100 g 29
Large white beans 146 mg/100 g 20
Quinoa 96 mg/100 g 13
Milk 88 mg/100 g 12
Choline
Beef liver 350 mg/100 g 63
Chicken liver 330 mg/100 g 60
Hard boiled eggs 230 mg/100 g 42
Smoked salmon 220 mg/100 g 40
Cooked salmon 91 mg/100 g 17
Soy protein powder 86 mg/100 g 16
Roasted chicken 79 mg/100 g 14
Peanut butter 66 mg/100 g 12
Almonds 52 mg/100 g 29
Cruciferous
vegetables 40 mg/100 g 7
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Table 1. Cont.
Foods Content RDA (%)
Betaine
Quinoa 630 mg/100 g 97
Rye 146 mg/100 g 60
Beets 129 mg/100 g 20
White bread 102 mg/100 g 16
Spinaches 89 mg/100 g 14
Bulgur 83 mg/100 g 13
Sweet potato 34.6 mg/100 g 5.3
Veal 33.9 mg/100 g 5.2
Oat flour 30.7 mg/100 g 4.7
Tilapia 26.3 mg/100 g 4
3.1. Folate
The effects of folic acid supplementation to normalize HHcy have been extensively studied in the
general population, as well as in CKD patients.
The term “folate” includes different forms of vitamin B9, including tetrahydrofolic acid (the active
form), methyltetrahydrofolate (the primary circulating form), methenyltetrahydrofolate, folinic acid,
folacin, and pteroylglutamic acid. Since the human body is unable to synthetize folate, it must be
supplied by the diet.
Folate is a crucial factor in the production of tetrahydrofolate (THF), a precursor of 5-MTHF
required for methionine synthase (MTR) enzyme activity. In the folate cycle, folate transfers one-carbon
moieties to different organic compounds, thus controlling SAM levels (Figure 3).
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There is a large body of evidence to indicate that folate therapy improves HHcy in the general
population, but the data are less clear in CKD patients [8,38,39].
Indeed, the benefits of folate supplementation in subjects with decreased renal function do not
seem to lie completely in the lowering of serum homocysteine. An emerging theory is that folate intake
improves endothelial dysfunction in CKD, without affecting homocysteine levels [40]. The reason
why folate therapy is able to reduce but not normalize HHcy in CKD is not completely understood,
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but it might be related to the decreased expression of folate receptor 2 and the subsequent impaired
sensitivity to homocysteine variations found in uremic patients [39].
A study on 341 hemodialysis patients at our center evaluated the treatment with 5-MTHF (50 mg
i.v.) vs. folic acid (5 mg/day oral) and found a better survival rate in patients treated with 5-MTHF,
in spite of no significant differences between the groups in terms of HHcy amelioration [7].
In this framework, a key issue is the role of folate supplementation on endothelial dysfunction,
another common feature of CKD and an important marker of vascular disease and atherosclerosis.
Vascular cells have been proven to be particularly sensitive to HHcy due to their lacking expression of
cystathionine β-synthase (CBS), a vitamin B6-dependent enzyme responsible for the hepatic reverse
transsulfuration pathway, and betaine-homocysteine S-methyltransferase (BHMT), which controls
the alternate betaine-homocysteine remethylation cycle [41,42]. The deficient CBS expression on
endothelial cells implies that homocysteine elimination can only occur through the folate and vitamin
B12-dependent remethylation pathway under the control of MTHFR and MTS. It has been proposed
that renal and vascular injury might share the same mechanism of regarding HHcy and reduced
availability of folic acid [42–45].
In order to clarify the disagreement of the various randomized controlled trials on the effectiveness
of folic acid-based homocysteine-lowering therapy on cardiovascular risk protection in renal patients,
Qin and colleagues performed two meta-analyses, pooling all the qualified randomized trials from
year 1966. In both cases, the results indicated that folic acid therapy is effective in cardiovascular risk
reduction by 10%, particularly in studies without grain fortification with folic acid and in those with a
lower prevalence of diabetes [46,47].
To summarize the data on folic acid supplementation and the related impact on global DNA
methylation status in CKD, the discrepancy in the results of the available studies might be partly
explicated by the fact that the paradigm connecting hypermethylation to transcriptional silencing
and hypomethylation to gene activation (Figure 1) is not always applicable in CKD. This view,
although valid for most genes, should be seen with a critical eye in the complex and multifaceted
scenario of renal failure, due to the involvement of uremia-related confounding factors (dyslipidemia,
anemia, inflammation, oxidative stress), and to the presence of other genetic elements (promoters,
regulatory regions, histone modifications, changes in chromatin conformation, long non-coding
RNAs, microRNAs) not directly related to the DNA methylation status. It has been proposed
that homocysteine accumulation in blood results in an intracellular rise of S-adenosylhomocysteine
(AdoHcy), a strong competitive methyltransferase inhibitor, that has been identified as a predictor of
cardiovascular events. Thus, high blood homocysteine levels and high intracellular, commonly found
in CKD patients, are associated with abnormal expression of genes regulated through methylation,
including imprinted genes and pseudoautosomal genes. However, such alterations can be reversed by
homocysteine-lowering therapy [48].
3.2. Cobalamin (Vitamin B12)
Vitamin B12, also known as cobalamin, is a nutrient with a key role for human health, being
involved as a coenzyme in many chemical reactions essential for human biochemistry. Vitamin B12
deficiency is a common cause of hyperhomocysteinemia and a frequent feature of CKD patients.
In one-carbon metabolism, folate serves as the methyl provider and vitamin B12 acts as cofactor for
the enzyme methionine synthase, thus folate and vitamin B12 equilibrium is a central regulator of
DNA methylation and the epigenetic network, in the general population as well as in nephropathic
patients [30,49].
Cobalamin is one of the most complex coenzymes existing in nature: the molecule is constituted
by a corrin ring and a dimethylbenizmidazole (DMB) moiety. The focal point of cobalamin structure
is the cobalt atom, held at the center of the corrin ring: it can form between four and six bonds,
and exists in three oxidation states: Co (III), Co (II), Co (I). Depending on the oxidative state of
cobalt, this atom will form a different number of bonds, from six to four; of these, four are always
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occupied by the nitrogen atoms of the planar corrin ring [50]. The fifth is usually an upper axial ligand
(defined as R-group), and in human cobalamin forms, this group usually corresponds to: (i) hydroxo
group (hydroxocobalamin, OHCbl); (ii) cyano group (cyanocobalamin, CNCbl); (iii) adenosyl group
(adenosylcobalamin, AdoCbl); (iv) methyl group (methylcobalamin, MeCbl).
OHCbl and CNCbl are the most commonly used forms in pharmaceutical formulations for
supplementation of vitamin B12. OHCbl is usually found in natural sources and in foods (Figure 3);
this form is more unstable compared to CNCbl, but it also binds more tightly to plasma serum proteins
(transcobalamin) and consequently persists for a longer time in the bloodstream.
On the other hand, CNCbl, the synthetic form of vitamin B12, is more suitable for pharmaceutical
products because of its greater chemical stability [51]. However, both CNCbl and HOCbl were
demonstrated to be equally absorbed at pharmacological dosages between 100 and 1000 µg. In target
tissues, both OHCbl and CNCbl are metabolized into the two vitamin B12 active forms: AdoCbl
in the mitochondria and MeCbl in the cytosol. These molecules are cofactors of several enzymes:
they catalyze enzymatic reactions which involve the making and breaking of the Co-C bond of
these cofactors. In particular, these two forms are directly required for the function of two enzymes,
mitochondrial methylmalonyl-CoA mutase (MUT) and cytosolic methionine synthase (MS) [52,53].
MUT employs AdoCbl to catalyze the conversion of L-methylmalonyl-CoA to succinyl-CoA. This is an
indispensable reaction involved in the fatty acid metabolism; additionally, succinil-CoA takes part
in the Krebs cycle, a complex of reactions fundamental for cellular energy production. MS, instead,
requires the methylated form of cobalamin and catalyzes the remethylation of homocysteine to Met,
using 5-methyltetrahydrofolate as the methyl donor. Met produced in this reaction is further converted
to SAM; finally, the methyl group of SAM can be donated to form a wide range of vitally important
methylated compounds [54]. The tight correlation between MeCbl and folate is accountable for the
megaloblastic anemia that occurs in both vitamin deficiencies frequently found in uremic patients,
resulting from inhibition of DNA synthesis during red blood cell production [55]. When cobalamin
levels become inadequate, DNA synthesis is impaired and cell cycle cannot progress from the G2
growth stage to the mitosis stage; this leads to continuing cell growth without division, leading
to macrocytosis.
Given the role of vitamin B12 human metabolic pathways, it is not uncommon to find low cobalamin
levels correlated to many different physio-pathological conditions, such as older age, pregnancy,
dietary deficiency, bariatric surgery, gastrointestinal diseases, drug treatments, and uremia-related
malnutrition. This deficiency is usually caused by malabsorption or reduced intake of foods rich of
cobalamin [8,56–58].
The impact of cobalamin deficiency on renal function and the benefits of vitamin B12
supplementation have been investigated in several studies. An analysis on a cohort of 2965 subjects
from the Framingham Heart Study, replicated in 4445 participants from NHANES 2003–2004, did not
highlight a relationship between B12 deficiency, albuminuria, and reduced kidney function [59].
Surprisingly, another study by Soho et al. showed an association between high vitamin B12 levels
and all-cause mortality in dialysis patients. The authors explain this unexpected finding in view of
the chronic inflammatory status characterizing uremic patients and postulate that this mechanism is
an evolutionary adaptation to prevent B12 uptake from infectious organisms in peripheral tissues.
Therefore, higher circulating B12 levels may actually reflect functional B12 deficiency in the peripheral
tissues, leading to hyperhomocysteinemia and increased cardiovascular risk [60].
However, it is also important to stress that the data on vitamin B12 measurement in serum
might be considerably influenced by the form of cobalamin assayed. The standard first-assay to
determine vitamin B12 status is the measurement of total serum vitamin B12, a widely available,
low cost, automated immune-chemiluminescence-based assay. However, the main limitation of
this method lies in the fact that it detects both the inactive forms bound to transcobalamin I and
transcobalamin III (referred to as holo-haptocorrin) and the active form of cobalamin in serum (referred
to as holo-transcobalamin, which is transcobalamin II-bound). The measurement of total serum vitamin
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B12 does not allow to discriminate between the active and inactive forms which is an important point,
as holo-haptocorrin does not transport cobalamin to cells [61]. Therefore, total serum B12 assay alone
is not a reliable biomarker of vitamin B12 status, because around 80% of that is bound to haptocorrin,
and not bioavailable for cellular uptake; therefore, patients with strong clinical features of cobalamin
deficiency may have serum cobalamin levels that lie within the reference range [62]. In the search of
other tests to assess the underlying functional or biochemical deficiency, plasma homocysteine, plasma
methylmalonic acid (MMA) and serum holotranscobalamin (holoTC) are the most useful, although
not widely used in the current practice, yet [63]. A study by Heil at al. validated on 360 samples the
diagnostic accuracy of serum total vitamin B12 and holoTC, confirmed that holoTC can replace total
vitamin B12 assay in screening for vitamin B12 deficiency, and determined the clinical decision point
for holoTC at 32 pmol/L [64].
The most common signs of vitamin B12 deficiency are hematologic changes and ineffective
erythropoiesis [65].
In ESRD, these conditions have been proven to further exacerbate anemia and may increase
erythropoietin stimulating agent resistance, the most significant factors found in ESRD population [66].
The only solution in the case of vitamin B12 deficiency is to supplement cobalamin in order to bring
serum levels within the physiological range. In general, patients with an irreversible cause should be
treated lifelong, while those with a reversible cause should be treated until the deficiency is corrected
and symptoms resolved.
Currently, the most used treatment for vitamin B12 deficiency consists of intramuscular cobalamin
injections, particularly in dialysis patients due to their compromised intestinal absorption of oral
formulations. Approximately 10% of the standard injectable dose of 1000 µg is absorbed, and this
allows for rapid replacement in patients with severe deficiency. The therapeutic protocol in the case of
important vitamin B12 deficiencies consists of injections of 1000 µg at least several times per week
for 1 to 2 weeks, then weekly until clear improvement is shown, followed then by monthly injections.
Hematologic response after this attach treatment is fast, with an increase in the reticulocyte count in
1 week and correction of megaloblastic anemia within 6 to 8 weeks.
The use of sublingual delivery is a growing trend in vitamin supplementation. This route of
administration avoids the issues of interference with absorption in the lower GI tract, and of the
first pass metabolism in the liver, and thus is a feasible alternative to injections [67]. Thanks to
this administration route, the active principle is directly picked up in the bloodstream because of
the highly vascularized tissue of the sublingual mucosa. Sublingual tablets, then, can produce an
immediate systemic effect, allowing drug absorption directly from the oral mucosa, which permits
a very fast distribution in the bloodstream and avoids the active principle degradation. Therefore,
the sublingual route has great advantages, such as the high bioavailability, fast action and the total
absence of pain. At present, available published and unpublished data come from non-renal patients.
Strong et al. demonstrated that sublingual treatment of diabetic patients with decreased serum vitamin
B12 concentration is as effective as intramuscular injection in correcting a low vitamin B12 status
over 6 months [68]. A recent retrospective study carried out by Bensky et al. on more than 4800
patients evaluated the differences between vitamin B12 serum levels after sublingual treatment and
intramuscular injections; this study demonstrated that sublingual and intramuscular routes are equally
efficient in raising vitamin B12 levels, underlining an even superior efficacy of the sublingual route,
which brought to an increase by 193% [69].
The safety and effectiveness of sublingual cobalamin supplementation is under investigation in
an ongoing study carried out at five Italian centers (unpublished data). This research pointed out two
primary endpoints: first, the evaluation of the response of a malnourished cohort of patients with
vitamin B12 deficiency to the administration of sublingual supplementation, with the aim to normalize
blood values; the second endpoint considered a cohort of patients who underwent bariatric surgery:
due to the well-known difficulties in maintaining appropriate levels of vitamin B12, caused both by a
reduced intake and a reduced gut absorption, the aim was to stabilize pre-surgical values. The patients
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were administered with a long acting sublingual formulation composed of 1000 µg of cobalamin
(750 µg cyanocobalamin, 250 µg methylcobalamin) specifically formulated to be administered once
weekly. Biochemical parameters, namely hemoglobin, mean corpuscular volume (MCV), hematocrit,
homocysteine and total serum vitamin B12, were collected in 195 patients at the time of recruitment (T0)
and after 6 months (T1), which is at the first follow up (data from T2, 12 months follow up, are currently
being collected).
The first preliminary data arising from this study show an increase of total serum vitamin B12
in 103 patients included up to now, 90.5% of them with a severe baseline vitamin B12 deficiency
(<400 pg/mL). After 3 months from the beginning of sublingual supplementations, total serum vitamin
B12 was increased by 4.3% in adult patients and 4.4% in the elderly (>65 years). In patients who
underwent bariatric surgery, the sublingual supplementation of vitamin B12, once weekly for 6 months,
allowed an increase by 17.8% of serum levels, thus halving the cases with severe deficiency.
3.3. Vitamin B6
Vitamin B6 is an essential nutrient belonging to the water-soluble B-vitamin group and exists
in different forms. The active one, pyridoxal 5′-phosphate, serves as a coenzyme in several enzyme
reactions of glucose, lipid, and amino acid metabolism, including the reversible transfer of a one-carbon
unit from serine to tetrahydrofolate (THF) to generate glycine and 5,10 MTHF [70,71].
Vitamin B6 can be found in several nutritional sources of animal and vegetal origin, although
cooking, storage, and processing might cause significant vitamin B6 losses, depending on the form
present in the food [72].
The benefits of vitamin B6 supplementation in CKD have been investigated in the context of
combined therapies with other B-vitamins and the available studies report contrasting results. In the
previous decade, the HOST and the DIVINe trials failed to prove such positive effects. The HOST
study was a large double-blind randomized controlled trial (2001–2006) on patients with HHcy (serum
homocysteine levels > 15 mol/L), 1305 of them with advanced CKD (creatinine clearance < 30 mL/min)
and 751 with ESRD [44]. The study showed that a daily therapy combining folic acid (40 mg), vitamin
B6 (100 mg) and vitamin B12 (2 mg) did not affect survival or incidence of vascular disease, regardless
of CKD stage [42]. Successively, the DIVINe trial (Diabetic Intervention with Vitamins to Improve
Nephropathy) tested vitamin B therapy (single daily tablet of B-vitamins containing 2.5 mg folic acid,
25 mg vitamin B6, and 1 mg vitamin B12) in 238 participants with diabetic nephropathy from five
different Canadian medical centers. Surprisingly, the group of treated patients had lower GFR and
higher rate of vascular events compared to the placebo group [73].
Besides, also studies on vitamin D deficiency and insufficiency have revealed a strong association
with increased overall mortality and deaths from specific aging-related diseases [74]. Actually,
25(OH)D deficiency has been related to unfavorable clinical outcomes and mortality risk in CKD
patients [75]. A study by Obeid et al. investigated the effects of a combined therapy of B-vitamins,
vitamin D, and calcium on epigenetic ageing markers [76]. The study was carried out on a limited
group of 63 subjects with normal renal function, but it has potential interest in nephrology, in
view of the well-known alterations occurring with age in the kidney, namely decline in functional
nephron mass, tubulointerstitial changes, glomerular basement membrane thickening, and progressive
glomerulosclerosis. The authors analyzed the degree of CpG methylation in three age-correlated genes,
aspartoacylase (ASPA), integrin alpha-IIb (ITGA2B), and cAMP-specific 30,50-cyclic phosphodiesterase
4C (PDE4C), comparing two arms of treatment, the first administrated of vitamin D3 + Ca-carbonate
and the second with vitamin D3 + Ca-carbonate added with 0.5 mg folic acid, 50 mg vitamin B6 and
0.5 mg vitamin B12. At the end of the one-year follow-up, the three genes showed different behaviors,
since methylation of ASPA and PDE4C was higher in the subjects receiving the therapy added with
B-vitamins, while methylation of ITGA2B was similar in the two groups. Moreover, in the D + Ca + B
treatment arm, lower baseline homocysteine levels were predictive of accelerated aging which was
also associated with younger chronological age in both groups [76].
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3.4. Methionine
Methionine (Met) is an essential sulfur-containing amino acid and a key factor in one-carbon
metabolism, as precursor of SAM. Thus, the nutritional intake of Met modulates the SAM/SAH ratio,
known as “methylation index” and ultimately the expression of genes regulated by methylation [77].
The main dietary sources of Met are Brazil nuts and animal proteins (meat, fish, eggs, dairy products,
and milk). Although Met cannot be completely eliminated from the diet since it is an essential
amino acid, there is a large evidence from in vitro, experimental and clinical studies on the benefits
of Met restriction in several pathological conditions related to accelerated ageing, including kidney
disease [78–81].
A recent rat model by Pradas and colleagues investigated the renoprotective role of Met restriction,
analyzing metabolomic and lipidomic profiling by mass spectrometry in renal cortex specimens from
3 groups of male rats, Adult (8-month-old) vs. Aged (26-month-old) vs. Aged fed with 80% Met
restricted diet. The results showed some changes in 59 differential metabolites between Adult and
Aged groups in the renal cortex metabolome. Moreover, Met restriction resulted in lipid metabolism
reprogramming, mainly affecting glycerophospholipids, docosanoids, and eicosanoids [82].
Another recent experimental study by Wang et al. found a higher survival rate and decreased levels
of senescence markers in C57BL/6 mice with a Met restricted diet through a mechanism of upregulation
of the transsulfuration pathway, increase of H2S production, and downregulated senescence markers
and AMPK (AMP-activated protein kinase) activation [83].
These data are in line with a previous report by Cooke et al. on the effects of Met restriction
in young and aged unilateral nephrectomized and 5/6 nephrectomized (5/6Nx) mice. The authors
showed that the groups with Met restricted diet had a better trend in terms of renal function parameters
(lower urinary albumin, creatinine, albumin-to-creatinine ratio, sulfur amino acids, and electrolytes)
and renoprotective biomarkers (clusterin and cystatin C). Moreover, Met restriction induced the
activation of genes involved in ion transport (Aqp2, Scnn1a, and Slc6a19), and attenuated kidney injury
progression inhibiting inflammatory and fibrosis pathways [84].
Met restriction has been also proven to slow down renal function decline associated to senescence
and metabolic dysfunction, improving renal insulin sensitivity, controlling glucose homeostasis, and
activating renoprotective genes [85,86].
3.5. Choline
Choline is involved in various mechanisms, such as neurotransmitter synthesis (acetylcholine),
cell-membrane signaling (phospholipids), lipid transport (lipoproteins), and one carbon metabolism,
acting similarly to folate as the methyl provider to support methionine regeneration. Although
liver cells are able to synthesize choline, such an endogenous amount is not sufficient for total
human requirements. For this reason, choline has been recognized as an essential nutrient, because a
supplementary intake by foods is necessary. Modern diet does not seem to provide a sufficient intake
of choline (RDA: 550 and 425 mg/day for men and women, respectively) [87,88]. In analogy with
other methyl donors, also choline deficiency results in HHcy and epigenetic dysregulation of genes
controlled through methylation.
In contrast, CKD patients tend to accumulate choline, because of the impaired choline elimination
that physiologically occurs through urine excretion. Hemodialysis is able to remove choline that
anyhow returns to baseline levels only after 6 h [89,90].
The extent of choline nutritional intake is a particularly important issue in nephropathic patients,
because its blood accumulation triggers a series of metabolic steps controlled by diet, gut microbiome,
and host interactions, leading to the release of trimethylamine N-oxide (TMAO), a proatherogenic
uremic toxin [91].
The link between gut microbial community, uremic toxins and one-carbon metabolism has been
widely investigated [30]. An experimental study by Romano et al. used a murine model with a
genetically engineered microbial community lacking for the choline-utilizing enzyme TMA-lyase
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(CutC). The authors found that mice with choline-consuming bacteria had a decreased bioavailability
of this essential methyl-donor, resulting in alterations to host epigenetic regulation. Concerning the
impact on renal function, the blood creatine levels were higher in CC+ colonized mice compared with
the CC− group, suggesting that impaired choline synthesis compromises creatine formation and leads
to renal function decline [92].
3.6. Betaine
Betaine is a nonessential nutrient found in various food sources that can also be synthesized from
choline and acts as an alternative methyl donor in the remethylation of homocysteine to Met, a reaction
catalyzed by the enzyme betaine homocysteine methyltransferase (BHMT). Thus, betaine is involved
in the control of the methylation index (SAM/SAH) ratio, and in the epigenetic gene regulation through
DNA methylation [24].
In mammalians, betaine is particularly abundant in the kidney, with a main osmoprotective
function in medulla cells. It is normally filtered by the glomerulus, and then almost completely
reabsorbed in the proximal tubule by cotransport with Na+ or H+ across the luminal plasma
membrane [93]. The role of betaine as an osmoprotectant in the kidney occurs through a well-described
process triggered by hyperosmotic stress.
Betaine is present in blood plasma at about 0.1 mM, partly derived from the diet and partly
by choline metabolism in the liver. While betaine content in the cortex is due to proximal tubule
reabsorption, cells in the kidney medulla uptake betaine primarily from the bloodstream via the
sodium and chloride coupled betaine/γ-aminobutyric acid GABA transport system (BGT1). BTG1 is an
integral membrane protein sited in the basolateral plasma membrane, predominantly expressed in the
thick ascending limb of Henle’s loop and in inner medullary collecting ducts [86]. An in vitro model of
cultured MDCK kidney cells showed that BGT1 protein expression can increase more than 10-fold
in response to hyperosmotic stress (500 mOsm) and such activation is due to a specific transcription
factor, called tonicity-responsive enhancer binding protein (TonEBP) [94,95].
3.7. Other Forms of Vitamin B: The Role of Niacin
Nicotinic acid and nicotinamide are collectively referred to as niacin (vitamin B3) and belong
to a group of coenzymes that control energy release from carbohydrates and for several redox
reactions. They represent the nutritional precursors of nicotinamide adenine dinucleotide (NAD) and
nicotinamide adenine dinucleotide phosphate (NADP). NAD and NADP, that serve as cofactors for
several cellular redox reactions, thus being essential players in the maintenance of cell metabolism
and respiration. There is growing evidence about the relationship between nutritional intake of
niacin, NAD(P) availability, and the activity of AD(P)-dependent enzymes that have been proven
to be important epigenetic regulators. Niacin intake is essential for the regulation of physiological
processes, preservation of genetic stability, and control of epigenetic changes that modulate metabolism
and ageing. Thus, niacin plays a crucial role in ageing-related diseases, like cancer, atherosclerosis,
metabolic disorders and renal failure [96].
4. New Insights in the Network of Methyl Donors, Hyperhomocysteinemia, Epigenetic
Landscape, Cardiovascular Risk and CKD Progression
Table 2 details the main clinical trials on the effects of treatment with B-vitamins on homocysteine
lowering in patients with various stages of CKD. Since there are several studies on supplementation
with folic acid (alone or with vitamins B6 and B12), we preferred to report in the table the results of
two successive meta-analyses by Qin et al., collecting the most qualified RCTs studies on the topic
published after 1966 [46,47].
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Table 2. Effects of treatment with B-vitamins on homocysteine lowering in patients with various stages
of CKD. The two meta-analyses by Qin et al. [46,47] collect the most relevant studies published after
1966 about homocysteine-lowering therapy with folic acid in cardiovascular risk prevention in patients
with kidney disease.
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Abbreviations: 5-MTHF, 5-Methyltetrahydrofolate; ACKD, advanced chronic kidney disease; CKD, chronic kidney
disease; CRP, C-reactive protein; ESA, erythropoietin stimulating agent; ESRD, end stage renal disease; MMA,
methylmalonic acid; OL, open label; RCT, randomized controlled trial.
The interest on the complex link between methyl donors, HHcy, epigenetic landscape,
cardiovascular risk and CKD progression is constantly renewed by the nephrology community.
Over the past few years, research on CKD genetics has moved its focus from single-gene studies
towards genome-wide linkage studies and epigenetic landscape.
Among human genome-wide studies, the CRIC (Chronic Renal Insufficiency Cohort) study
investigated DNA methylation patterns associated with rapid loss of kidney function by the Infinium
HumanMethylation 450 BeadChip, a method to assess the methylation status of 485,577 cytosine
positions in the human genome. The study focused on 40 study participants, 20 of them were the
ones the highest decline rates in eGFR, and 20 with the lowest. The results showed that genes
involved in epithelial to mesenchymal transition and renal fibrosis, namely NPHP4, IQSEC1 and TCF3,
were more largely hypermethylated patients with stable kidney function. Other genes of oxidative
stress, cell signaling, and inflammatory pathways (NOS3, NFKBIL2, CLU, NFKBIB, TGFB3, TGFBI)
were differentially methylated, confirming the regulatory role of epigenetic changes in CKD through
activation or suppression of key genes [97].
Given the well-assessed relationship between DNA methylation and CKD, efforts have been made
to introduce in the clinical nephrology practice two demethylating agents, 5-azacytidine and decitabine,
currently in use for some specific forms of myelodysplastic syndrome and acute myeloid leukemia.
A potential role of 5-azacytidine against renal fibrosis progression has been described by Bechtel
et al. in a mouse model of renal fibrosis induced by folic acid. The group investigated the role of
hypermethylation of RASAL1 gene that encodes for rasGAP-activating-like protein 1, an inhibitor of
the Ras oncoprotein, highly expressed in fibrotic kidneys. The study revealed that hypermethylation
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resulted in a decreased expression of RASAL1 gene and triggered fibroblast switch to an activated
phenotype, persisting also after the mitigation of renal injury. The administration of 5-azacytidine led to
a significantly reduced rise in activated fibroblasts, as well as the expression of α-smooth muscle actin
and type I collagen. This effect was also confirmed in cultured fibrotic human kidney fibroblasts, as the
exposure to 5-azacytidine normalized cell, their proliferative activity as well as the expression of type I
collagen and α-smooth muscle actin. An interesting point in this murine model was the differential
expression of DNMT gene, as fibrotic mouse kidneys showed an increased DNMT1 expression, but not
DNMT3a or DNMT3b expression compared to control kidneys, suggesting a specific role of DNMT1 in
RASAL1 methylation and kidney fibrosis progression [98].
Similar findings for hydralazine were recently reported in another murine model of ischemia-
reperfusion injury by Tampa et al., aimed at exploring the epigenetic mechanism underlying the
development of kidney fibrosis and the AKI-to-CKD evolution. The model confirmed the role
of the promoter hypermethylation of RASAL1 gene in the shift from physiological regeneration
to tubulointerstitial fibrogenesis. The demethylating agent hydralazine, commonly used as an
antihypertensive drug, effectively induced RASAL1 promoter demethylation, thus resulting in
attenuated renal fibrosis, improved renal function [99].
Finally, the role of uremic toxins, in particular metabolic products of gut microbiome, deserves
special attention, since recent reports have suggested that renal impairment on atherosclerosis is
only partially attributable to the elevation of plasma homocysteine. Spence et al. found that the
worsening of carotid plaque burden, expressed by total plaque area (TPA), in patients with reduced
eGFR, results from a combined effect of HHcy and other uremic toxins, including indoxyl sulfate,
p-cresyl sulfate, asymmetric dimethylarginine (ADMA), thiocyanate, trimethylamine and its oxidative
product trimethylamine N-oxide (TMAO) [100].
Such findings open the way to potential therapeutic and nutritional approaches in an effort to
reduce cardiovascular risk in uremic patients. Besides treatment with thiols like mesna to control
HHcy [101], there are other interventions like dietary restriction of L-carnitine from red meat and
phosphatidylcholine from egg yolks for TMAO reduction [102]. Another useful strategy is represented
by overnight daily dialysis, because of its double advantage to normalizes homocysteine levels and to
reduce uremic toxins like ADMA, TMAO and other products of gut microbiome [103].
5. Conclusions
Epigenetic regulation in patients with CKD and ERSD is strictly related to the interplay of
nutritional intake and supplementation of B-vitamins and methyl donors with uremic milieu.
Homocysteine is undoubtedly the key factor in methylome status and epigenetic landscape, although
the peculiar scenario of uremia is influenced by other confounding factors, like inflammation,
gut microbiome, oxidative stress, and lifestyle habits. A better understanding of this complex network
may help the clinicians in the challenging riddle of interindividual variations in CKD progression and
to identify patient-tailored therapeutic approaches based on their own nutritional deficiencies.
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